Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.

Evans K, Duan J, Pritchard T, Jones CD, McDermott L, Gu Z, Toscan CE, El-Zein N, Mayoh C, Erickson SW, Guo Y, Meng F, Jung D, Rathi KS, Roberts KG, Mullighan CG, Shia CS, Pearce T, Teicher BA, Smith MA, Lock RB.

Clin Cancer Res. 2019 Jul 15;25(14):4493-4503. doi: 10.1158/1078-0432.CCR-19-0551. Epub 2019 Apr 23.

PMID:
31015346
2.

Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia.

Jing D, Huang Y, Liu X, Sia KCS, Zhang JC, Tai X, Wang M, Toscan CE, McCalmont H, Evans K, Mayoh C, Poulos RC, Span M, Mi J, Zhang C, Wong JWH, Beck D, Pimanda JE, Lock RB.

Cancer Cell. 2018 Dec 10;34(6):906-921.e8. doi: 10.1016/j.ccell.2018.11.002.

PMID:
30537513
3.

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.

Moradi Manesh D, El-Hoss J, Evans K, Richmond J, Toscan CE, Bracken LS, Hedrick A, Sutton R, Marshall GM, Wilson WR, Kurmasheva RT, Billups C, Houghton PJ, Smith MA, Carol H, Lock RB.

Blood. 2015 Sep 3;126(10):1193-202. doi: 10.1182/blood-2014-12-618900. Epub 2015 Jun 26.

4.

Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts.

Toscan CE, Rahimi M, Bhadbhade M, Pickford R, McAlpine SR, Lock RB.

Org Biomol Chem. 2015 Jun 14;13(22):6299-312. doi: 10.1039/c5ob00779h.

PMID:
25967739
5.

High-throughput screening of human leukemia xenografts to identify dexamethasone sensitizers.

Toscan CE, Failes T, Arndt GM, Lock RB.

J Biomol Screen. 2014 Dec;19(10):1391-401. doi: 10.1177/1087057114546550. Epub 2014 Aug 7.

PMID:
25104793

Supplemental Content

Loading ...
Support Center